← All Halozyme Therapeutics, INC filings

Halozyme Therapeutics, INC 8-K filings

NASDAQ
HALO
Halozyme Therapeutics, INC
8-K: Halozyme Therapeutics Announces Preliminary 2023 Financial Results, Revenue Expected to Reach $832 Million
Halozyme Therapeutics estimates its 2023 revenue to be between $827 million and $832 million, with net income between $292 million and $297 million.